Valoctocogene roxaparvovec and emicizumab for hemophilia A without inhibitors: effectiveness and value. Final report. Institute for Clinical and Economic Review - Rind, D; Walton, S; Agboola, F (2020)
. Accessed January 24, 2023 at: